Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Official Title

A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer


The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Trial Description

Primary Outcome:

  • Metastasis Free Survival (MFS)
Secondary Outcome:
  • Overall Survival (OS)
  • Time to Pain Progression
  • Time to Opiate Use for Prostate Cancer Pain
  • Time to First Use of Cytotoxic Chemotherapy
  • Time to First Use of New Antineoplastic Therapy
  • Time to Prostate-Specific Antigen (PSA) Progression
  • FACT-P Global Score
  • Quality of Life as assessed by EQ-5D-5L and QLQ-PR25

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society